Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2026)

Avalo Therapeutics (AVTX) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $446000.0 in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 60.43% year-over-year to $446000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $446000.0 (up 60.43% YoY) and the FY2025 annual result came in at $434000.0, down 69.65% from the prior year.
• Non-Current Deferred Tax Liability climbed to $446000.0 in Q1 2026, from $434000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.4 million in Q4 2024 to a low of $122000.0 in Q1 2022.
• A 5-year average of $283294.1 and a median of $162000.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability jumped 822.58% — and 2025, when it plunged 69.65%.
• Tracing AVTX's Non-Current Deferred Tax Liability over 5 years: stood at $141000.0 in 2022, then rose by 9.93% to $155000.0 in 2023, then jumped by 822.58% to $1.4 million in 2024, then sank by 69.65% to $434000.0 in 2025, then rose by 2.76% to $446000.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $446000.0 (Q1 2026), $434000.0 (Q4 2025), and $304000.0 (Q3 2025), per Business Quant data.